Sézary Syndrome: A Case Report of a Variant of Cutaneous T-cell Lymphoma
Christian E. Amiwero *
Division of Haematology, Department of Laboratory Redeemers Health, Village Hospital, Redemption City, Mowe, Ogun State, Nigeria.
Olanrewaju A. Ajayi
Department of Internal Medicine, Redeemers Health Village Hospital, Redemption City, Mowe, Ogun State, Nigeria.
Lere P. Oluwadare
Department of Paediatrics, Redeemers Health Village Hospital, Redemption City, Mowe, Ogun State, Nigeria.
Pauline K. Akowundu
Department of Paediatrics, Redeemers Health Village Hospital, Redemption City, Mowe, Ogun State, Nigeria.
Ilemobayo Promise Dayo
Department of Internal Medicine, Redeemers Health Village Hospital, Redemption City, Mowe, Ogun State, Nigeria.
Odutola I. Odetunde
Division of Paediatric Nephrology, Department of Paediatrics, Redeemer’s Health Village, Redemption City, Mowe, Ogun State, Nigeria.
*Author to whom correspondence should be addressed.
Abstract
Aim: This case report highlights a rare variant of cutaneous T-cell lymphoma, known as Sézary syndrome, observed at Redeemers Health Village Hospital, a multispecialty tertiary academic centre in southwestern Nigeria.
Presentation of Case: The report describes a 36-year-old man diagnosed with stage IVB T4N3M1B2 (TNMB system) refractory Sézary syndrome, a rare and aggressive form of mycosis fungoides and a type of cutaneous T-cell lymphoma. The diagnosis was established on the basis of the patient’s medical history and findings from physical examination, histopathological analysis and blood film examination. This assessment revealed skin tumours, lymphadenopathy, particularly in the submental and axillary regions, visceral involvement indicated by splenomegaly, and erythroderma affecting more than 90% of the body surface area. Histopathology showed malignant T-cell infiltration in the skin, while immunophenotyping indicated CD3 and CD4 positivity (markers that are notably elevated in Sézary syndrome) and CD30 negativity. The blood film differential analysis identified more than 2,000 Sézary cells.
In resource-limited countries in sub-Saharan Africa, analysis of an extended panel of markers is often restricted. However, a consensus reached in a study by Ulrickson et al. (2013) emphasised that the examination findings observed in this case are sufficient for diagnosing cutaneous lymphomas. The proposed treatment plan for this patient included topical corticosteroids, topical bexarotene and oral bexarotene.
Discussion: Sézary syndrome (SS) is a transformed form of mycosis fungoides that belongs to a family of cutaneous T-cell lymphomas (CTCLs). It is characterised by erythroderma affecting at least 80% of the body surface area, together with generalised lymphadenopathy and circulating malignant T cells (known as Sézary cells) in the peripheral blood. Diagnosing CTCL can be challenging, particularly in African settings, because of the rarity of the disease and its similarity to other dermatological conditions, such as psoriasis. Therefore, a high index of suspicion, together with clinical history and thorough physical examination, is essential for diagnosing CTCL and Sézary syndrome. Additional diagnostic tools include histopathological examination of skin lesions, blood film analysis, immunophenotyping and imaging studies. Following diagnosis, the National Comprehensive Cancer Network (NCCN, 2026) recommends initiating therapies that are well tolerated, have lower cumulative toxicity, reduce immunosuppression and offer greater efficacy over extended periods.
Conclusion: The choice of treatment depends on the disease stage at presentation and the presence or absence of targeted markers. Treatment options range from topical corticosteroids and ultraviolet B (UVB) phototherapy to psoralen plus ultraviolet A (PUVA) phototherapy, extracorporeal photopheresis (ECP), systemic chemotherapy and targeted monoclonal antibodies. Patients with Sézary syndrome have a poor prognosis and often experience a reduced quality of life, with a median survival of 1–4 years. However, mogamulizumab for patients with advanced Sézary syndrome, brentuximab for CD30-positive patients and bexarotene have been reported to improve response rates and increase progression-free survival.
Keywords: Skin tumour, cytokines, immunophenotype, cutaneous T cell lymphoma, Sezary syndrome